Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta Pharmaceutical Investing
Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1 Pharmaceutical Investing
Pfizer's XELJANZ® Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis Pharmaceutical Investing
New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission Pharmaceutical Investing
AbbVie Announces First Provincial Reimbursement for VENCLEXTA® with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia in Quebec Pharmaceutical Investing
Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration Pharmaceutical Investing
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative Life Science Investing
Bristol Myers Squibb Awards "Golden Tickets" to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs Pharmaceutical Investing
FDA Approves Merck's KEYTRUDA® as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery Pharmaceutical Investing
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19 Pharmaceutical Investing
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HMLP, NVAX Investors, Lead Plaintiff Deadlines Set Pharmaceutical Investing
